The GNPTG Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the SK-HEP-1 human hepatic adenocarcinoma cell line, featuring targeted disruption of the GNPTG gene. This product provides a heterogeneous mixture of edited cells, enabling robust loss-of-function studies without clonal selection artifacts. The polyclonal format ensures diverse mutational events across the cell population, offering a more physiologically relevant model for gene knockout research while maintaining consistency for high-throughput applications.
SK-HEP-1 is an adherent, ascites-derived cell line established from a patient with liver adenocarcinoma, widely employed in hepatocarcinoma research. This cell line exhibits characteristic epithelial morphology and has been extensively characterized for studies in cancer cell signaling, metabolism, and metastasis. Its hepatic origin makes it particularly suitable for investigating liver-specific lysosomal functions and the implications of GNPTG disruption in hepatocellular carcinoma progression.
GNPTG encodes the gamma subunit of GlcNAc-1-phosphotransferase, which initiates mannose-6-phosphate (M6P) synthesis on lysosomal hydrolases. It functions with the alpha/beta subcomplex (GNPTAB) to catalyze transfer of GlcNAc-1-phosphate. The M6P tag is recognized by CI-MPR and CD-MPR receptors in the trans-Golgi network, sorting enzymes like cathepsin D and beta-hexosaminidase to lysosomes. GNPTG is transcriptionally regulated by TFEB, TFE3, and MITF in response to lysosomal stress. Knockout of GNPTG abolishes M6P biosynthesis, causing missorting and secretion of lysosomal enzymes, leading to lysosomal dysfunction and accumulation of substrates such as glycosphingolipids.
In the SK-HEP-1 hepatic adenocarcinoma context, perturbed lysosomal function caused by GNPTG loss mimics aspects of lysosomal storage disorders and provides a window into lysosomal dysfunction in cancer. Lysosomal positioning and enzyme trafficking are increasingly recognized as modulators of tumor cell invasion, autophagy, and drug resistance. This knockout model allows dissection of how impaired M6P-dependent targeting alters lysosomal proteolytic capacity, autophagic flux, and metabolic rewiring in liver cancer cells, contributing to a better understanding of the putative pro-tumorigenic roles of lysosomal defects.
This polyclonal knockout population supports immunoblotting confirmation of GNPTG disruption, lysosomal enzyme activity assays (cathepsin B/L), M6P immunodetection, and Lysotracker staining. Subcellular fractionation and RNA-seq reveal trafficking defects and transcriptional responses. Functional cell migration and invasion assays combined with drug treatments illuminate the role of lysosomal enzyme sorting in cancer metastasis. This model is valuable for mucolipidosis III gamma studies, lysosomal biogenesis research, and therapeutic screening. For product information, contact Ascent Research.
